BIO-GENE ANNOUNCES POSITIVE SAFETY RESULTS OF FLAVESONE IN EARLY...

BIO-GENE ANNOUNCES POSITIVE SAFETY RESULTS OF FLAVESONE IN EARLY STAGE TOXICOLOGY

•   Formal assessment in acute and short term repeated studies show good safety profile of flavesone
•   Bio-Gene has now commenced longer term studies
•   Data generated to be used to support regulatory programs
  Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene” or “the Company”), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, has successfully completed initial toxicology studies in acute and seven-day repeated dose testing of flavesone with positive results demonstrating a favourable safety profile.
  Flavesone is the active constituent contained in the products being developed under the FlavocideTM brand. The favourable safety profile demonstrated in short term toxicity data will now enable the commencement of longer term, 28-day oral and dermal toxicity studies with an international regulatory accredited toxicology testing organisation.
  “The findings from the acute and seven-day toxicology studies indicate that flavesone has a high safety threshold and we are excited to be able to initiate longer term studies today which will form part of our future registration filings,” said Richard Jagger, Bio-Gene’s CEO-elect. “As well as demonstrating product efficacy, a critical part of registering any new insecticide is to demonstrate that it is safe to mammals at expected exposure rates. Our initial results, which we now need to confirm in longer term studies, indicate that FlavocideTM will meet this requirement.”